<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122355</url>
  </required_header>
  <id_info>
    <org_study_id>4-2008-0530</org_study_id>
    <nct_id>NCT01122355</nct_id>
  </id_info>
  <brief_title>Comparison of Fenofibrate and Niacin in Patients With Hypertriglyceridemia and Low High-Density Lipoprotein (HDL)-Cholesterol</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy and tolerability of fenofibrate 160 mg
      and niacin 1500 mg in patients with hypertriglyceridemia and low HDL-cholesterol. The primary
      end point is the percent change of apoB/A1 and the secondary end points are other lipid
      parameters and biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percent change of apoB/A1</measure>
    <time_frame>after 16 weeks of drug treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Hypertriglyceridemia With Low HDL-cholesterol</condition>
  <arm_group>
    <arm_group_label>niacin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>fenofibrate arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lipid modification</intervention_name>
    <description>1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks</description>
    <arm_group_label>niacin arm</arm_group_label>
    <arm_group_label>fenofibrate arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Triglyceride 150-500 mg/dL and HDL-cholesterol &lt; 45 mg/dL after 8 week dietary run in
             period

          -  20-79 years old

        Exclusion Criteria:

          -  Low-density lipoprotein (LDL)-cholesterol â‰¥ 130 mg/dL without any lipid-modifying drug

          -  History of cerebrovascular or cardiovascular diseases

          -  Creatinine &gt; 2.0 mg/dL

          -  Transaminase &gt; 2x upper limit of normal

          -  Gall bladder disease

          -  Cancer

          -  Pregnant or breast feeding women

          -  History of adverse events associated with test drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Hak Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>professor of division of Cardiology</affiliation>
  </overall_official>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>May 28, 2010</last_update_submitted>
  <last_update_submitted_qc>May 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sang Hak Lee/associate professor</name_title>
    <organization>Yonsei University, College of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Niacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

